Mechanisms of joint damage in gout: evidence from cellular and imaging studies.
The clinical course of gout is initially characterized by acute self-limited joint inflammation, but long-standing disease is often associated with chronic inflammation followed by the development of erosive joint damage, which can result in long-term functional impairment. Preventing joint damage is now a major focus of therapeutic intervention in gout. New light has been shed on the mechanisms leading to cartilage and bone damage in patients with this disease. Here, we discuss basic science studies focusing on the cellular immunology of bone and cartilage in gout and the effects of monosodium urate crystals on signaling pathways, cytokine release and the function of osteoclasts, osteoblasts and chondrocytes. We then explore the use of advanced imaging modalities (including MRI, ultrasonography, CT and dual-energy CT) to investigate pathology in gout, as they provide new ways to visualize joint tissues. These modalities vary in their ability to detect the various pathological features of gout and have different clinical applications. Imaging provides information about the inflammatory nature of the joint lesion, position and size of tophaceous deposits, and extent of bone and cartilage damage. Imaging is also increasingly being used to monitor the progression of joint damage and regression of tophi with effective urate-lowering therapy.
Department of Molecular Medicine and Pathology, University of Auckland, Park Road, Grafton, Auckland 1023, New Zealand. f.mcqueen@auckland.ac.nz
Fiona M
FM
McQueen
Ashika
A
Chhana
Nicola
N
Dalbeth
D001168:Arthritis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D002358:Cartilage, Articular / Q000378:metabolism / Q000473:pathology; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D003952:Diagnostic Imaging / Q000379:methods*; D018450:Disease Progression; D006073:Gout / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000150:complications / Q000188:drug therapy; D007596:Joints / Q000473:pathology* / Q000503:physiopathology
D016207:Cytokines; D006074:Gout Suppressants